Evidence map›Paper›PMID 39964571›Full record

ArticleBiotechnology letters2025

In-silico evaluation of potential plant-based tyrosinase inhibitors for cosmetic and pharmaceutical applications.

Jyoti Srivastava, Sukhendra Singh, Rupika Sinha

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jyoti SrivastavaDepartment of Biotechnology, Motilal Nehru National Institute of Technology Allahabad, Prayagraj, Uttar Pradesh, 211004, India.
Sukhendra SinghDepartment of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Mathura, Uttar Pradesh, 281406, India.
Rupika SinhaDepartment of Biotechnology, Motilal Nehru National Institute of Technology Allahabad, Prayagraj, Uttar Pradesh, 211004, India. rupika@mnnit.ac.in.ORCID http://orcid.org/0000-0001-8410-0831

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosinase is involved in a critical step of melanin synthesis; therefore, tyrosinase inhibitors are gaining more importance in the medicinal and cosmetic industry for the treatment of different pigmentary disorders. In the last decades, mushroom tyrosinase was used as a standard enzyme for the identification and advancement of most tyrosinase inhibitors. Due to differences in structure and substrate specificity between mushroom and human tyrosinase, there is a need for a more specific study with human tyrosinase. Additionally, the tyrosinase inhibitors which are currently in use have various side effects, therefore, safer inhibitors from natural sources are required. Different tyrosinase inhibitors from natural sources (aloesin, norartocarpetin, hesperetin, morin and taxifolin) were evaluated for an effective eco-friendly whitening agent using different bioinformatics tools. To check the efficacy and safety of the selected compounds ADME analysis was performed which showed that all the selected compounds fulfilled most of the parameters of general drug discovery. Docking of selected ligands was performed against the predicted structure of human tyrosinase; and the binding affinity (in kcal/mol) of kojic acid, aloesin, norartocarpetin, hesperetin, morin and taxifolin were obtained to be - 5.6, - 7.2, - 7.6, - 7.5, - 7.3 and - 7.2 respectively. Among all the selected ligands, norartocarpetin had the lowest binding affinity, i.e., - 7.6 kcal/mol, which showed that norartocarpetin could be used as a potent tyrosinase inhibitor. This bioactive compound is widely distributed in Moraceae plants and therefore, poses as a natural solution to various melanin-based dermatological issues and it can have a potential application in pharmaceuticals and cosmetic industries for the treatment of pigmentary disorders.

Indexed as

CosmeticsEnzyme InhibitorsMonophenol MonooxygenaseAgaricalesComputer SimulationHumansMolecular Docking SimulationCosmeticsEnzyme InhibitorsMonophenol MonooxygenaseBioactive compoundDockingIn-silico studiesPhyto-constituentsTyrosinase inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.